Can tumor location predict effectiveness of bevacizumab conduc-ted in the fi rst-line setting for metastatic colorectal cancer
暂无分享,去创建一个
E. Vasile | A. Falcone | C. Vivaldi | M. Lencioni | L. Ginocchi | C. Caparello | S. Caponi | G. Musettini | M. Lucchesi
[1] C. Fuchs,et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial , 2014, The Lancet.
[2] S. K. Baek,et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] T. Hansen,et al. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[4] D. Shin,et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. , 2013, The Lancet. Oncology.
[5] Ying Cheng,et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] A. Jubb,et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.